Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing small-molecule therapies for cancer, liver disease and inflammatory conditions. Its drug-development platform is based primarily on agonists of the A3 adenosine receptor, a biological target that the company believes may help regulate disease-related inflammatory and cancer cells while having limited effects on healthy cells.

The company’s leading investigational product is namodenoson, an orally administered A3 adenosine receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis, and advanced hepatocellular carcinoma. Can-Fite has also developed piclidenoson, another A3 receptor agonist studied for inflammatory and autoimmune diseases, including rheumatoid arthritis and psoriasis.

Founded in Israel, Can-Fite conducts its research and clinical-development activities through international programs and collaborations. The company is headquartered in Petah Tikva, Israel, and is led by founder and Chief Executive Officer Dr. Pnina Fishman. Its products remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $1.60 to $1.70
• 50-Day Range: $1.62 to $3.40
• 52-Week Range: $1.60 to $12.30
• Volume: 22,386 shs
• Average Volume: 892,751 shs
• Market Capitalization: $1.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Can-Fite BioPharma has a consensus price target of $44.00, representing about 2,616.0% upside from its current price of $1.62.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CANF.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

21.00% of the stock of Can-Fite BioPharma is held by institutions.

Company Calendar

• Last Earnings: 11/30/2021
• Today: 10/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Can-Fite BioPharma: $44.00
• High Price Target: $80.00
• Low Price Target: $8.00
• Potential Upside/Downside: +2,616.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $405 thousand
• Price / Sales: 4.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 1,070,000
• Free Float: N/A
• Market Cap: $1.73 million
• Optionable: Not Optionable
• Beta: 1.16